clinical trials, this large and adequately powered trial points to a lack of clinical efficacy for remote ischaemic conditioning in this setting. As such, it might be time to abandon this form of cardioprotection in favour of more effective therapies to extend and improve the lives of these patients.
Intermittent ischaemia and reperfusion cycles, or ischaemic conditioning, has been viewed as a promising potential cardioprotective technique since its first description by Murry and colleagues in 1986. 1 The most encouraging iteration of this technique to emerge over the past three decades has been the application of a modified blood pressure cuff placed on the upper arm to induce cycles of remote, transient ischaemia that relay protection to the heart via predominantly neurohormonal mechanisms.
2 Remote ischaemic conditioning showed early potential in reducing infarct size after myocardial infarction in animal models.
3,4 The initial CONDI-1 trial, although small (n=333), suggested that remote ischaemic conditions used as an adjunct to the gold standard therapy of primary percutaneous coronary intervention (PPCI) for ST-elevation myocardial infarction (STEMI) improved the myocardial salvage index 5 as well as left ventricular systolic function at 30 days in patients at risk of large infarcts. 6 The results of the RIC-STEMI trial (n=258) echoed those of CONDI-1, with remote ischaemic conditioning showing additional benefits in reducing cardiac deaths and hospitalisations and increasing the overall mean improvement of ejection fraction after 1 year. 7 Medium-term follow-up data (at a median 3·6 years) from the LIPSIA CONDITIONING study (n=696) showed that remote ischaemic conditioning combined with post-conditioning reduced new heart failure diagnoses compared with remote ischaemic conditioning alone. 8 None of these trials showed a reduction in infarct size when remote ischaemic conditioning was applied; however, cardiac MRI data suggest the ability of remote ischaemic conditioning to induce positive ventricular remodelling in the absence of absolute infarct size reduction. 9 In The Lancet, Derek Hausenloy and colleagues 10 report the findings of the combined CONDI-2/ERIC-PPCI trial, a large and appropriately powered randomised controlled trial to address whether remote ischaemic conditioning as an adjunct to PPCI can improve the clinical outcomes of patients with STEMI when compared with PPCI alone. The trial was a pragmatic combination of two very similar protocol designs. This finding was consistent in prespecified subgroup analyses by age, presence of diabetes, pre-PPCI TIMI flow, ischaemia time, or infarct location. Furthermore, the 12-month incidence of major adverse cardiac and cerebrovascular events (a composite of all-cause death, reinfarction, unplanned revascularisation, and stroke) did not differ significantly between the groups (HR 1·09 [95% CI 0·90-1·32], p=0·38).
Hausenloy and colleagues should be praised for their robust and clinically relevant trial to assess the role of remote ischaemic conditioning in the current landscape of STEMI management. The findings show clearly that the use of remote ischaemic conditioning around the time of PPCI for STEMI adds no clinical benefit for outcomes assessed within 1 year of the procedure. 10 A cautionary note pertains to the follow-up time of only 1 year: our current understanding of cardiac remodelling post-STEMI is that the clinical benefits derived from cardioprotective interventions might not manifest until after 2 years, or perhaps longer, 11 and as such the trial could have benefited from a longer follow-up time. The authors also acknowledge that the remote ischaemic conditioning protocol used (four 5-min cycles of upper arm cuff inflations and deflations applied before PPCI) might have been insufficient to induce an adequate neurohormonal response in some patients, although this protocol has been shown to be the most efficacious one in animal and subsequent clinical studies. 12 The role of remote ischaemic conditioning in improving the lives of patients with STEMI has been thrown sharply into question. Despite the early promise of a number of preclinical and smaller proof-of-principle
